SG11201602884WA - Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome - Google Patents

Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome

Info

Publication number
SG11201602884WA
SG11201602884WA SG11201602884WA SG11201602884WA SG11201602884WA SG 11201602884W A SG11201602884W A SG 11201602884WA SG 11201602884W A SG11201602884W A SG 11201602884WA SG 11201602884W A SG11201602884W A SG 11201602884WA SG 11201602884W A SG11201602884W A SG 11201602884WA
Authority
SG
Singapore
Prior art keywords
hydromorphone
naloxone
pain
treatment
dysfunction syndrome
Prior art date
Application number
SG11201602884WA
Inventor
Helen Kathleen Danagher
Hassan Mohammad
Malcolm Walden
Geoffrey Gerard Hayes
Jonathon Oliver Whitehouse
Thinnayam Naganathan Krishnamurthy
Rincon Ricardo Alberto Vargas
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP13192793 priority Critical
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Priority to PCT/EP2014/074537 priority patent/WO2015071380A1/en
Publication of SG11201602884WA publication Critical patent/SG11201602884WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
SG11201602884WA 2013-11-13 2014-11-13 Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome SG11201602884WA (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP13192793 2013-11-13
PCT/EP2014/074537 WO2015071380A1 (en) 2013-11-13 2014-11-13 Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome

Publications (1)

Publication Number Publication Date
SG11201602884WA true SG11201602884WA (en) 2016-05-30

Family

ID=49578189

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201602884WA SG11201602884WA (en) 2013-11-13 2014-11-13 Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome

Country Status (17)

Country Link
US (2) US9814710B2 (en)
EP (1) EP3068397A1 (en)
JP (1) JP6232135B2 (en)
KR (2) KR20160060768A (en)
CN (1) CN105916505A (en)
AU (1) AU2014350135B2 (en)
BR (1) BR112016009749A8 (en)
CA (1) CA2929909C (en)
DE (1) DE112014005175T5 (en)
EA (1) EA030310B1 (en)
IL (1) IL245027D0 (en)
MX (1) MX2016006279A (en)
NZ (1) NZ719087A (en)
PH (1) PH12016500666A1 (en)
SG (1) SG11201602884WA (en)
UA (1) UA116405C2 (en)
WO (1) WO2015071380A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012028656A2 (en) 2010-05-10 2016-08-09 Euro Celtique Sa combination of active loaded granules with additional assets
EP2568968B1 (en) 2010-05-10 2017-07-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
EA030310B1 (en) 2013-11-13 2018-07-31 Эро-Селтик С.А. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
CA2847781C (en) * 2014-03-28 2019-03-12 Purdue Pharma Reducing drug liking in a subject
US20160256451A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
WO2016193456A2 (en) * 2015-06-03 2016-12-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3965256A (en) 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
IE49324B1 (en) 1979-12-19 1985-09-18 Euro Celtique Sa Controlled release compositions
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4987136A (en) 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
HU190619B (en) 1983-11-11 1986-09-29 Bezzegh,Denes,Hu Process for producing tablets with controlled dissolution of active ingredients
EP0164669B1 (en) 1984-06-13 1991-01-23 Röhm Gmbh Process for coating pharmaceutical forms
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4785000A (en) 1986-06-18 1988-11-15 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US5004613A (en) 1987-07-27 1991-04-02 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
FR2653337B1 (en) 1989-10-23 1992-02-07 Dow Corning Sa Element has sustained release and method for manufacture.
JPH03232814A (en) 1990-02-08 1991-10-16 Shin Etsu Chem Co Ltd Production of sustained release tablet
DE4325465B4 (en) 1993-07-29 2004-03-04 Jurna, Ilmar, Prof. Dr.med. Oral pharmaceutical preparation for pain therapy
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE4443105C2 (en) 1994-12-03 1997-03-13 Hoechst Ag A process for preparing tablets containing molsidomine-
US6488961B1 (en) 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
DE19651551C2 (en) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioid antagonist-containing galenic formulation
PL190293B1 (en) 1997-02-14 2005-11-30 Gödecke Aktiengesellschaft Stabilisation of naloxone hydrochloride
EP1009387B1 (en) 1997-07-02 2006-04-12 Euro-Celtique S.A. Stabilized sustained release tramadol formulations
AT210983T (en) 1997-11-03 2002-01-15 Stada Arzneimittel Ag Stabilized combination product containing naloxone and an opiate analgesic
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP2266564B1 (en) 1997-12-22 2013-03-13 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist
TWI223598B (en) 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
US6071952A (en) 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
CA2389650C (en) 1999-11-01 2008-12-09 Rodeva Limited Composition for treatment of constipation and irritable bowel syndrome
DE10003757A1 (en) 2000-01-28 2001-08-02 Knoll Ag Ibuprofen active ingredient preparation
JP2003522146A (en) 2000-02-08 2003-07-22 ユーロ−セルティーク,エス.エイ. Oral opioid agonist preparation resistant to external pressure
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040115133A1 (en) 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
DE60238756D1 (en) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid containing arzneiform against misuse
DE60216078T2 (en) 2001-05-11 2007-07-05 Endo Pharmaceuticals Inc. Opioid containing arzneiform against misuse
AU2002314968B2 (en) 2001-06-08 2006-12-07 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
AU2002323032B2 (en) 2001-08-06 2005-02-24 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
HU0401195A3 (en) 2001-08-06 2006-11-28 Euro Celtique Sa Compositions to prevent abuse of opioids containing aversive agent and process of their preparation
AT466016T (en) 2001-08-23 2010-05-15 Organon Nv Process for for the preparation of a 14-hydroxynormorphinone derivative
DE10144726B4 (en) 2001-09-11 2006-10-05 T-Mobile Deutschland Gmbh Method for the provision and allocation of telephone numbers in a telecommunications network
DE10146275A1 (en) 2001-09-18 2003-04-24 Gruenenthal Gmbh Combination of selected opioids with muscarinic antagonists for the treatment of urinary incontinence
CA2478558C (en) 2002-03-14 2012-09-11 Euro-Celtique, S.A. Naltrexone hydrochloride compositions
AU2003224040B2 (en) 2002-04-05 2006-06-22 Mundipharma Pty Limited Pharmaceutical preparation containing oxycodone and naloxone
DE10215131A1 (en) 2002-04-05 2003-10-16 Euro Celtique Sa Stable pharmaceutical preparation useful for the treatment of pain, especially severe pain, without causing side-effects comprises oxycodone and naxolone in retarded release formulation
NZ536975A (en) 2002-07-04 2006-10-27 Janssen Pharmaceutica Nv Solid dispersions of a poorly soluble bioactive compound comprising two different polymer matrixes
EP1638607A1 (en) 2003-04-08 2006-03-29 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
WO2004091622A1 (en) 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
PT2368554E (en) 2003-04-08 2015-02-06 Progenics Pharm Inc Pharmaceutical formulations containing methylnaltrexone
EP1641441B1 (en) 2003-04-30 2014-03-12 Purdue Pharma L.P. Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
US9114199B2 (en) 2003-07-31 2015-08-25 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing acrylic copolymer for controlled delivery of therapeutic agent
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
WO2005034859A2 (en) 2003-10-03 2005-04-21 Elite Laboratories Inc. Extended release formulations of opioids and method of use thereof
US20050079221A1 (en) 2003-10-10 2005-04-14 Groenewoud Pieter Jurjen Ibuprofen narcotic composition and method for making same
US20050165038A1 (en) 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
MXPA06008931A (en) 2004-02-06 2007-01-26 Euro Celtique Sa Methods for making 3-o-protected morphinones and 3-o-protected morphinone dienol carboxylates.
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
EP2319499A1 (en) 2005-01-28 2011-05-11 Euro-Celtique S.A. Alcohol resistant dosage forms
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
US20050232987A1 (en) 2004-03-12 2005-10-20 Viswanathan Srinivasan Dosage form containing a morphine derivative and another drug
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
US7700626B2 (en) 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
JP2006076971A (en) 2004-09-13 2006-03-23 Basf Ag Orally disintegrating tablet
US20060088594A1 (en) 2004-10-08 2006-04-27 Pilgaonkar Pratibha S Highly compressible controlled delivery compositions of metformin
GB0423103D0 (en) 2004-10-19 2004-11-17 Boots Healthcare Int Ltd Therapeutic agents
AU2006206454A1 (en) 2005-01-20 2006-07-27 Progenics Pharmaceuticals, Inc. Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US20090214640A1 (en) 2005-03-04 2009-08-27 Intelgenx Cporp. Delayed release pharmaceutical oral dosage form and method of making same
JP4741865B2 (en) 2005-03-24 2011-08-10 共和薬品工業株式会社 Method for producing pergolide tablets
US20070026025A1 (en) 2005-04-12 2007-02-01 Aquegel Cosmetics, Llc Topical ointment and method for making and using same
CA2609719A1 (en) 2005-05-25 2006-11-30 Janssen Pharmaceutica N.V. Pediatric formulation of topiramate
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070059360A1 (en) 2005-07-29 2007-03-15 Ashish Jaiswal Water-dispersible anti-retroviral pharmaceutical compositions
US20070048364A1 (en) 2005-08-04 2007-03-01 Yingxu Peng Free flowing granules containing carbomer
DE102005047561A1 (en) 2005-10-04 2007-04-05 Bayer Healthcare Ag Drug delivery system, useful to treat and/or prevent e.g. thromboembolic disease, comprises 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)-1,3-oxazolidine-5-yl)-methyl)-2-thiophene carboxamide with fast release active substance
DE602006017257D1 (en) 2005-12-14 2010-11-11 Hoffmann La Roche HCV Prodrug FORMULATION
US20070141147A1 (en) 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US7799790B2 (en) 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
SA2709B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
DE102006051020A1 (en) 2006-10-26 2008-04-30 Evonik Röhm Gmbh Use of enteric (meth)acrylate copolymers in controlled-release oral pharmaceutical dosage forms as drug matrix formers to reduce the effect of ethanol-induced release rate increase or decrease in vitro
CA2734333A1 (en) 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
GB2447898B (en) 2007-03-24 2011-08-17 Reckitt Benckiser Healthcare A tablet having improved stability with at least two actives
AU2009268011B2 (en) 2008-07-07 2013-02-28 Mundipharma Pty Limited Use of opioid antagonists for treating urinary retention
EP2379066B1 (en) 2008-09-16 2014-03-26 Imuneks Farma Ilaç Sanayi Ve Ticaret A.S. Use of opioid antagonists for the preparation of a medicament in the treatment of retinal degenerative diseases
NZ601200A (en) 2008-09-18 2014-02-28 Purdue Pharma Lp Pharmaceutical dosage forms comprising poly(epsilon-caprolactone)
US20110229562A1 (en) 2008-09-24 2011-09-22 Evonik Roehm Gmbh Ph-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol
EP2341899B1 (en) 2008-09-24 2014-12-17 Evonik Röhm GmbH Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
CN104257600A (en) 2008-10-30 2015-01-07 格吕伦塔尔有限公司 Novel And Potent Tapentadol Dosage Forms
US20100143486A1 (en) 2008-12-10 2010-06-10 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
CA2750144C (en) 2008-12-31 2016-10-25 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
CA2749315A1 (en) 2009-01-09 2010-07-15 Tobias Ritter Fluorine containing compounds and methods of use thereof
EP2389159A1 (en) 2009-01-22 2011-11-30 Noramco, Inc. Process for preparing particles of opioids and compositions produced thereby
DK2393487T3 (en) 2009-02-06 2017-01-23 Egalet Ltd Pharmaceutical compositions resistant to abuse
AU2010216150B2 (en) 2009-02-17 2015-05-14 Mallinckrodt Llc Process for the reductive alkylation of normorphinans
EP2398806A1 (en) 2009-02-23 2011-12-28 Mallinckrodt LLC (+)-morphinanium n-oxides and processes for their production
JP5784507B2 (en) 2009-02-23 2015-09-24 マリンクロッド エルエルシー (+)-Morphinanium quaternary salt and method for producing the same
US20100227876A1 (en) 2009-03-06 2010-09-09 Rechfensen Llp Methods of Reducing Side Effects of Analgesics
HUE042105T2 (en) 2009-03-10 2019-06-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
JP5619131B2 (en) 2009-03-18 2014-11-05 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツングEvonik RoehmGmbH Controlled release pharmaceutical composition having resistance to the effects of ethanol using a coating comprising a polymer mixture and an excipient
KR101571198B1 (en) 2009-03-18 2015-11-23 에보니크 룀 게엠베하 Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
BRPI1015108A2 (en) 2009-04-02 2016-04-26 Shire Llc opioid dicarboxylic acid-linked amino acid and peptide prodrugs and their uses
WO2010120232A1 (en) 2009-04-14 2010-10-21 Yki, Ytkemiska Institutet Ab A prodrug comprising beta-keto carboxylic acid, beta-keto carboxylic acid salt or beta-keto carboxylic acid ester for drug delivery
US20100291151A1 (en) 2009-04-21 2010-11-18 Auspex Pharmaceuticals, Inc. 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
EP2421508B1 (en) 2009-04-24 2016-12-14 Omya International AG Particulate material for controlled release of active ingredients
WO2010141505A1 (en) 2009-06-01 2010-12-09 Protect Pharmaceutical Corporation Abuse-resistant delivery systems
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
CN102803267A (en) 2009-06-11 2012-11-28 马林克罗特有限公司 Preparation of 6-alpha-amino n-substituted morphinans by catalytic hydrogen transfer
FR2946533A1 (en) 2009-06-12 2010-12-17 Ethypharm Sa Reduction of plasmatic fluctuations of opioids.
WO2011009020A2 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
ES2428938T3 (en) 2009-07-22 2013-11-12 Grünenthal GmbH Dosage form resistant to manipulation and stabilized against oxidation
NZ596667A (en) 2009-07-22 2013-09-27 Gruenenthal Chemie Hot-melt extruded controlled release dosage form
GB0914338D0 (en) 2009-08-17 2009-09-30 Johnson Matthey Plc Improved process
US9493477B2 (en) 2009-09-08 2016-11-15 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
US20110077222A1 (en) 2009-09-30 2011-03-31 Mallinckrodt Inc. Sustained-Release Opiate and Opiate Derivative Compositions
EP3064064A1 (en) 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US20110150989A1 (en) 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
CN102111808B (en) 2009-12-25 2012-04-25 华为技术有限公司 Method and device for reporting buffer status
BR112012028656A2 (en) 2010-05-10 2016-08-09 Euro Celtique Sa combination of active loaded granules with additional assets
EP2568968B1 (en) 2010-05-10 2017-07-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
AP3441A (en) * 2010-05-10 2015-10-31 Euro Celtique Sa Pharmaceutical compositions comprising hydromorphone and naloxone
CA2805974C (en) 2010-08-13 2019-11-26 Euro-Celtique S.A. Use of binders for manufacturing storage stable formulations
GB201020895D0 (en) 2010-12-09 2011-01-26 Euro Celtique Sa Dosage form
JP5864606B2 (en) 2010-12-28 2016-02-17 ユーロ−セルティーク エス.エイ. Combination of opioid agonists and opioid antagonists in the treatment of Parkinson's disease
CN103998025A (en) 2011-10-06 2014-08-20 格吕伦塔尔有限公司 Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist
CA2881144A1 (en) 2012-11-09 2014-05-09 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
EA030310B1 (en) 2013-11-13 2018-07-31 Эро-Селтик С.А. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome

Also Published As

Publication number Publication date
NZ719087A (en) 2017-12-22
DE112014005175T5 (en) 2016-07-21
CN105916505A (en) 2016-08-31
WO2015071380A1 (en) 2015-05-21
JP6232135B2 (en) 2017-11-15
JP2016539937A (en) 2016-12-22
CA2929909A1 (en) 2015-05-21
AU2014350135B2 (en) 2017-08-31
EA030310B1 (en) 2018-07-31
BR112016009749A8 (en) 2018-01-30
IL245027D0 (en) 2016-05-31
US20180064705A1 (en) 2018-03-08
US10258616B2 (en) 2019-04-16
CA2929909C (en) 2018-08-21
KR20160060768A (en) 2016-05-30
MX2016006279A (en) 2016-09-07
PH12016500666A1 (en) 2016-06-13
US9814710B2 (en) 2017-11-14
UA116405C2 (en) 2018-03-12
AU2014350135A1 (en) 2016-05-12
US20160296516A1 (en) 2016-10-13
EP3068397A1 (en) 2016-09-21
EA201690974A1 (en) 2016-09-30
KR20180016651A (en) 2018-02-14

Similar Documents

Publication Publication Date Title
DK2815066T3 (en) SELECTIVE CORRODABLE Borehole article and method of use
EP2986339A4 (en) Nasal stimulation devices and methods
HK1212209A1 (en) Tubulysin compounds, methods of making and use
EP2720623A4 (en) Fistula treatment devices and methods
GB201413234D0 (en) Security device and method of manufacture
ZA201505926B (en) Wound dressing and method of treatment
IL227440A (en) Ballstent device and methods of use
EP2709562A4 (en) Tissue restraining devices and methods of use
HK1221398A1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders pi3k
EP2981328A4 (en) System and method for electrical stimulation of anorectal structures to treat anal dysfunction
ZA201502503B (en) Hppd variants and methods of use
EP2836270A4 (en) Systems and methods related to the treatment of back pain
SG11201600185UA (en) Therapeutically active compounds and their methods of use
HK1220995A1 (en) Microbial-based waste water treatment compositions and methods of use thereof
GB201320729D0 (en) Therapeutic compounds and their use
SG11201406894VA (en) Oilfield apparatus and methods of use
HUE039560T2 (en) Microclosures and related methods for skin treatment
IL239369D0 (en) Pirocyclic morphinans and their use
IL243833D0 (en) Therapeutically active compounds and their methods of use
GB201400322D0 (en) Exercise Apparatus and method of use thereof
EP2658551A4 (en) Treatment of erectile dysfunction and other indications
EP2988786A4 (en) Selective drug delivery compositions and methods of use
EP2970317A4 (en) Pyrimido-diazepinone compounds and methods of treating disorders
HK1220891A1 (en) Expandable body device and method of use
EP2934340A4 (en) Biopsy device and method of use